Overview

The Safety of Four Different Dose Levels of Wobenzym in HIV-Positive Patients

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To study the safety and efficacy of four different doses of Wobenzym (an enzyme combination consisting of pancreatin, papain, bromelain, trypsin, lipase, amylase, chymotrypsin, and rutin) in patients with HIV infection whose CD4 count is between 250 and 400 cells/mm3. To evaluate the effect of Wobenzym on certain surrogate markers associated with progression of HIV disease.
Phase:
Phase 1
Details
Lead Sponsor:
Mucos Pharma GmbH and Co
Treatments:
Wobenzym